Research Article| Volume 36, ISSUE 5, P489-497, November 1987

Download started.


A new low-dose estrogen oral contraceptive combination: Effect on endocrine parameters and lipid status

      This paper is only available as a PDF. To read, Please Download here.


      In this study the variations of endocrine and metabolic parameters of 39 women treated with a new oral contraceptive combination containing 20 mcg of ethinylestradiol and 150 mcg of desogestrel were examined.
      Gonadotropins and androgen presented a significant decrease, showing the efficiency of suppression of the pituitary-ovarian activity and of the contraceptive effect. The significant increase of SHBG and the correspoding reduction of free testosterone reflect the estrogenic environment of this pill and the low androgenicity of desogestrel.
      During the observation period, plasma levels of total cholesterol, trglycerides, LDL-C and HDL2-C were not altered, whereas total phospholipids, HDL-C and HDL3-C increased significantly. Besides a general positive effect on the main lipid parameters involved in atherogenic process, this pill also presented an optimal subjective tolerability.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fraser I.S.
        A health perspective of hormonal contraceptives.
        Acta Obstet Gynecol Scand Suppl. 1986; 134: 33
        • Plunkett E.R.
        Contraceptive steroid age and the cardiovascular system.
        Am J Obstet Gynecol. 1982; 142: 747
        • Royal College of General Practitioners
        Oral contraception study: mortality among oral contraceptive users.
        Lancet. 1977; ii: 727
        • Vessey M.P.
        • Mc Pherson K.
        • Johnson B.
        Mortality among women participating in Oxford Family Planning Association contraceptive study.
        Lancet. 1977; ii: 731
        • Fotherby K.
        Oral contraceptives, lipids and cardiovascular disease.
        Contraception. 1985; 31: 367
        • Wynn V.
        • Niththyananthan R.
        The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins.
        Am J Obstet Gynecol. 1982; 142: 766
        • Mann J.I.
        Progestogens in cardiovascular disease: An introduction to epidemiological data.
        Am J Obstet Gynecol. 1982; 142: 752
        • Kay C.R.
        Progestogens and arterial disease: Evidence from the Royal College of General Practitioners' study.
        Am J Obstet Gynecol. 1982; 142: 762
        • Meade T.W.
        Effects of progestogens on the cardiovascular system.
        Am J Obstet Gynecol. 1982; 142: 776
        • Gordon T.
        • Castelli W.P.
        • Hjortland M.C.
        • Konnel W.B.
        • Danber T.R.
        The Framingham study — High density lipoproteins as a protective factor against coronary heart disease.
        Am J Med. 1977; 62: 707
        • Miller N.E.
        The evidence for the antiatherogenicity of high density lipoprotein in man.
        Lipids. 1978; 13: 914
      1. High-density lipoproteins.
        Lancet. 1981; i (Anonymous): 478
        • Bradley D.D.
        • Wingerd J.
        • Petitti D.B.
        • Krauss R.H.
        • Ramcharan S.
        Serum high-density lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins.
        N Engl J Med. 1978; 299: 17
        • Silfverstolpe G.
        • Johnson P.
        • Samsioe G.
        • Svanborg A.
        • Gustafson A.
        Lipid metabolic studies in oophorectomized women.
        Acta Endocrinol. 1981; 96: 527
        • Bagget B.
        • Nash H.A.
        Effects of contraceptive steroids on serum lipoproteins and cardiovascular disease scrutinized at workshop in Bethesda. Contraception. 21. 1980: 115
        • Powell M.G.
        • Hedlin A.M.
        • Cerskus I.
        • Kakis G.
        • Prudham D.
        • Rosenrot P.
        Effects of oral contraceptives on lipoprotein lipids: A prospective study.
        Obstet Gynecol. 1984; 63: 764
        • Astedt B.
        Oral contraception and some debatable side effects.
        Acta Obstet Gynecol Scand Suppl. 1982; 105: 17
        • Bottinger L.D.
        • Bomarigeklund G.
        • Westerholm B.
        Oral contraceptives and thromboembolic disease. Effects of lowering estrogen content.
        Lancet. 1980; i: 1099
        • Meade T.W.
        • Greenberg G.
        • Thompon S.G.
        Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-mcg oestrogen preparations.
        Br Med J. 1980; 280: 1157
        • Royal College of General Practitioners' oral contraception study
        Further analyses of mortality in oral contraceptive users.
        Lancet. 1981; i: 541
        • Bergink E.W.
        • Borglin N.E.
        • Klottrup P.
        Effects of desogestrel and levonorgestrel in low dose oestrogen oral contraceptives on serum lipoproteins.
        Contraception. 1982; 25: 477
        • Knoop R.H.
        • Walden C.E.
        • Wahl P.N.
        • Hoover J.
        Effects of oral contraceptives on lipoprotein, triglyceride and cholesterol: Relationships to estrogen and progestin potency.
        Am J Obstet Gynecol. 1982; 142: 725
        • Hirvonen E.
        • Maelkoenen M.
        • Mamminen V.
        Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
        N Engl J Med. 1981; 304: 560
        • Tikkanen M.J.
        • Nikkila E.A.
        • Kuusi T.
        • Sipinen S.
        Different effects of two progestins on plasma high density lipoproteins (HDL2) and postheparin plasma hepatic lipase activity.
        Atherosclerosis. 1981; 40: 365
        • Silfverstolpe G.
        • Gustafson A.
        • Samsioe G.
        • Svanborg A.
        Lipid metabolic studies in oophorectomized women — Effects of three different progestogens.
        Acta Obstet Gynecol Scand Suppl. 1979; 88: 89
        • Larsson-Cohn V.
        • Wallentin L.
        • Zadar G.
        Effects of three different combinations of ethinyloestradiol and levonorgestrel on plasma lipids and high-density lipoproteins.
        Acta Obstet Gynecol Scand Suppl. 1979; 88: 57
        • Bergink E.W.
        • Holma P.
        • Pyorala T.
        Effects of oral contraceptive combination containing levonorgestrel or desogestrel on serum proteins and binding.
        Scand J Clin Lab Invest. 1983; 41: 663
        • Madden J.D.
        • Milewich L.
        • Parker C.R.
        The effect of oral contraceptive treatment on the serum concentration of dehydroisoandrosterone sulfate.
        Am J Obstet Gynecol. 1978; 132: 380
        • Fern M.
        • Rose D.P.
        • Fern E.B.
        Effect of oral contraceptives on plasma androgenic steroid and their precursors.
        Obstet Gynecol. 1978; 51: 541
        • Wiebe R.H.
        • Morris C.V.
        Effect of an oral contraceptive on adrenal and ovarian androgenic steroids.
        Obstet Gynecol. 1984; 63: 12
        • El Makhzangy M.N.
        • Wynn V.
        • Lawrence D.M.
        Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids.
        Clin Endocrinol. 1979; 10: 39
        • Larsson-Cohn V.
        • Fahraeus L.
        • Wallentin L.
        • Zador G.
        Effects of the estrogenicity of levonorgestrel/ethinylestradiol combinations on the lipoprotein status.
        Acta Obstet Gynecol Scand Suppl. 1982; 105: 37
        • De Backer G.
        • Rossenev M.
        • Deslypere J.P.
        Discriminative value of lipids and apoproteins in coronary heart disease.
        Atherosclerosis. 1982; 42: 197
        • Kim H.J.
        • Kalkhoff R.K.
        Sex steroid influence on triglyceride metabolism.
        J Clin Invest. 1975; 56: 888